Saturday November 21 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Amgen Incorporated

Over the past quarter century, Amgen has pioneered the methods by which human proteins that play a role in disease processes are identified, isolated, produced in quantity and used as therapeutics. Today, Amgenhas research programs in inflammation, metabolic disorders and osteoporosis, neurology, oncology and hematology. The company has R&D facilities in Thousand Oaks, CA; San Francisco, CA; Cambridge, MA; Cambridge, UK; Regensburg, Germany; and Seattle, WA.

With expertise in proteins, small molecules, antibodies, peptibodies, and nucleic acids, Amgen’s scientists can pursue the study of disease, choose the best target for a disease and then use the modality most likely to have an effect on that target. This approach positions Amgen as one of the only companies with capabilities across a range of modalities.

Mastering the tools of therapeutic development, as they emerge, is crucial to Amgen’s ongoing success. Accordingly, the company has invested at least 20 percent of product sales in research and development each year since 1994—a total of approximately $2.0 billion in 2004.


Contact Details:
One Amgen Center Drive
Thousand Oaks
CA
91320 1799
United States of America
Tel:805 447 1000
Fax:805 447 1010
Email:
WWW:

www.amgen.com/




Loading...

Recent Publications by Amgen Incorporated:

IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma.
Besides classic T cell-derived T-helper type 2 (Th2) cytokines such as...
13th November, 2009
Department of Inflammation Research, Amgen, Seattle, WA, USA. Clin Exp Allergy. 2009 Nov 3.
DOI Direct Link
Tetrahydroquinoline derivatives as CRTH2 antagonists.
A series of tetrahydroquinoline-derived inhibitors of the CRTH2 receptor...
10th November, 2009
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. Bioorg Med Chem Lett. 2009 Oct 25.
DOI Direct Link
Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells.
Erythropoietin (Epo) binds and activates the Epo receptor (EpoR) on the...
6th November, 2009
Amgen Inc, One Amgen Center, Thousand Oaks, CA 91320, United States. J Immunol Methods. 2009 Nov 1.
DOI Direct Link
Different Modes of Inhibitor Binding to Prolyl Hydroxylase by Combined Use of X-ray Crystallography and NMR Spectroscopy of Paramagnetic Complexes.
In aqueous solution, azaquinolone inhibitors bind to prolyl 4-hydroxylase...
6th November, 2009
Department of Molecular Structure, Protein Science, Chemistry Research and J Am Chem Soc. 2009 Nov 3.
DOI Direct Link
Relationship between Passive Permeability, Efflux, and Predictability of Clearance from in vitro Metabolic Intrinsic Clearance.
In vitro intrinsic metabolic clearance (CL(int)) is used routinely for...
31st October, 2009
1 Amgen Inc; Drug Metab Dispos. 2009 Oct 29.
DOI Direct Link

View more Amgen Incorporated research publications.

BioNews Results for Amgen Incorporated:

AuburnEURs place on Amgen Tour of California route holds promise
Auburn Journal:  Nov 15 2009 9:26AM Matching: amgen
Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
Entrepreneur.com:  Nov 13 2009 7:42PM Matching: amgen
County nonprofits unite to help residents through financial storm
Simi Valley Acorn:  Nov 13 2009 9:57PM Matching: amgen
Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
FinanzNachrichten.de:  Nov 12 2009 2:29PM Matching: amgen
Amgen to Present at 18th Annual Credit Suisse Healthcare Conference
Reuters:  Nov 12 2009 3:15PM Matching: amgen
Promote your company here: BioNewsCast - Press Release Distribution

View more Amgen Incorporated news.

Amgen Incorporated Clinical Trials:

Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis

Amgen Incorporated Patents:

US Patent No.Title
7524940 OB protein compositions and methods
7531321 Fibroblast growth factor-like molecules and uses thereof
7528244 Regulators of apoptosis
7524874 Vanilloid receptor ligands and their use in treatments
7514438 Melanin concentrating hormone receptor antagonist

View more Amgen Incorporated patents.

Amgen Incorporated (AMGN) Financial information Links from Barchart

AMGN Quote from from Barchart.com
AMGN Chart from from Barchart.com
AMGN Profile from from Barchart.com
AMGN Opinion from from Barchart.com

View more Amgen Incorporated finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 366 individuals from Amgen Incorporated using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1474 times since April 2007, the link to the organisation's website has been followed 172 times

Recent Search Terms used to find this page: amgen org chart | exact number of R D employees at Amgen | amgen e-mail list | amgen chemistry research and discovery | pegsunercept patent | amgen organization chart | organizational chart amgen | organization chart amgen | structure e-mail adresses amgen | amgen company profile 2009 | .

Search for more companies in Thousand Oaks

Search for more companies in CA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Amgen Incorporated

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.